Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

657 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Potential role of IgM-enriched immunoglobulin as adjuvant treatment for invasive meningococcal disease.
Tascini C, Fraganza F, Salani F, Sozio E, Rossi M, Sbrana F, Carannante N, Chiesa MD, Ripoli A, Bertolino G, Di Pietro M, Bartoloni A, Menichetti F; GISA/SIMIT Meningitis Study Group. Tascini C, et al. Among authors: di pietro m. Intensive Care Med. 2018 Feb;44(2):261-262. doi: 10.1007/s00134-017-4957-z. Epub 2017 Nov 9. Intensive Care Med. 2018. PMID: 29124316 No abstract available.
Clinical presentation and outcome of twenty cases of Invasive Meningococcal Disease due to Serogroup C - Clonal complex 11 in the Florence province, Italy, 2015-2016.
Fusco FM, Baragli F, Del Pin B, Spina R, Calamai I, Pecile P, Riccobono E, Nieddu F, Moriondo M, Miglietta A, Voller F, Fazio C, Stefanelli P, Di Pietro M. Fusco FM, et al. Among authors: di pietro m. J Infect. 2017 Feb;74(2):210-213. doi: 10.1016/j.jinf.2016.12.001. Epub 2016 Dec 8. J Infect. 2017. PMID: 27940176 No abstract available.
Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2020 Oct 21;18(1):405. doi: 10.1186/s12967-020-02573-9. J Transl Med. 2020. PMID: 33087150 Free PMC article. Clinical Trial.
Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data From the PRESTIGIO Registry.
Galli L, Parisi MR, Poli A, Menozzi M, Fiscon M, Garlassi E, Francisci D, Di Biagio A, Sterrantino G, Fornabaio C, Degli Antoni A, Angarano G, Fusco FM, D'Arminio Monforte A, Corbelli GM, Santoro MM, Zazzi M, Castagna A; PRESTIGIO Study Group. Galli L, et al. Open Forum Infect Dis. 2020 Sep 26;7(11):ofaa456. doi: 10.1093/ofid/ofaa456. eCollection 2020 Nov. Open Forum Infect Dis. 2020. PMID: 33241063 Free PMC article.
Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial.
Perrone F, Piccirillo MC, Ascierto PA, Salvarani C, Parrella R, Marata AM, Popoli P, Ferraris L, Marrocco-Trischitta MM, Ripamonti D, Binda F, Bonfanti P, Squillace N, Castelli F, Muiesan ML, Lichtner M, Calzetti C, Salerno ND, Atripaldi L, Cascella M, Costantini M, Dolci G, Facciolongo NC, Fraganza F, Massari M, Montesarchio V, Mussini C, Negri EA, Botti G, Cardone C, Gargiulo P, Gravina A, Schettino C, Arenare L, Chiodini P, Gallo C; TOCIVID-19 investigators, Italy. Perrone F, et al. J Transl Med. 2021 Oct 21;19(1):442. doi: 10.1186/s12967-021-03094-9. J Transl Med. 2021. PMID: 34674735 Free PMC article. No abstract available.
Parietal intrahemispheric source connectivity of resting-state electroencephalographic alpha rhythms is abnormal in Naïve HIV patients.
Babiloni C, Del Percio C, Lizio R, Lopez S, Pennica A, Roma P, Correr V, Cucciolla F, Toma G, Soricelli A, Di Campli F, Aceti A, Teti E, Sarmati L, Crocetti G, Ferri R, Lorenzo I, Galli M, Negri C, Angarano G, Saracino A, Lepore L, Di Pietro M, Fusco FM, Vullo V, D'Ettorre G, Pagliano P, Di Flumeri G, Celesia BM, Gentilini Cacciola E, Di Perri G, Calcagno A, Stocchi F, Ferracuti S, Onorati P, Andreoni M, Noce G. Babiloni C, et al. Among authors: di perri g, di pietro m, di flumeri g, di campli f. Brain Res Bull. 2022 Apr;181:129-143. doi: 10.1016/j.brainresbull.2022.01.015. Epub 2022 Jan 29. Brain Res Bull. 2022. PMID: 35101575
Systemic Inflammation-Based Biomarkers and Survival in HIV-Positive Subject With Solid Cancer in an Italian Multicenter Study.
Raffetti E, Donato F, Pezzoli C, Digiambenedetto S, Bandera A, Di Pietro M, Di Filippo E, Maggiolo F, Sighinolfi L, Fornabaio C, Castelnuovo F, Ladisa N, Castelli F, Quiros Roldan E. Raffetti E, et al. Among authors: di filippo e, di pietro m. J Acquir Immune Defic Syndr. 2015 Aug 15;69(5):585-92. doi: 10.1097/QAI.0000000000000682. J Acquir Immune Defic Syndr. 2015. PMID: 26167619
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F, Katlama C, Masia M, Bernardino JI, Saumoy M, Pozniak A, Gatell JM, Martinez E; NEAT022 Study Group. Gonzalez-Cordon A, et al. J Antimicrob Chemother. 2020 Nov 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292. J Antimicrob Chemother. 2020. PMID: 32737482 Clinical Trial.
Switching from boosted PIs to dolutegravir decreases soluble CD14 and adiponectin in high cardiovascular risk people living with HIV.
González-Cordón A, Assoumou L, Moyle G, Waters L, Johnson M, Domingo P, Fox J, Stellbrink HJ, Guaraldi G, Masiá M, Gompels M, De Wit S, Florence E, Esser S, Raffi F, Behrens G, Pozniak A, Gatell JM, Martínez E; NEAT022 Study Group. González-Cordón A, et al. J Antimicrob Chemother. 2021 Aug 12;76(9):2380-2393. doi: 10.1093/jac/dkab158. J Antimicrob Chemother. 2021. PMID: 34120186 Clinical Trial.
657 results